Skip to main content
SpringerLink
Log in

Researcher of the month

  • MUW researcher of the month
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Ausgewählte Literatur

  1. Singer J, Fazekas J, Wang W, Weichselbaumer M, Matz M, Mader A, Steinfellner W, Meitz S, Mechtcheriakova D, Sobanov Y, Willmann M, Stockner T, Spillner E, Kunert R, Jensen-Jarolim E. Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients. Mol Cancer Ther. 2014;13(7):1777–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Singer J, Jensen-Jarolim E. IgE based immunotherapy of cancer: challenges and chances. Allergy. 2014;69(2):137–49.

  3. Singer J, Weichselbaumer M, Stockner T, Mechtcheriakova D, Sobanov Y, Wrba F, Horvat R, Thalhamer J, Willmann M, Jensen-Jarolim E. Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Mol Immunol. 2012;50(4):200–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Singer J, Jensen-Jarolim E. IgE-based immunotherapy of cancer – a comparative oncology approach. J Carcinog Mutagen. 2014;5(3):1000176.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Petricevic B, Laengle J, Singer J, Sachet M, Fazekas J, Steger G, Bartsch R, Jensen-Jarolim E, Bergmann M. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med. 2013;11:307.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Spillner E, Plum M, Blank S, Miehe M, Singer J, Braren I. Recombinant IgE antibody engineering to target EGFR. Cancer Immunol Immunother. 2012;61(9):1565–73.

    Article  CAS  PubMed  Google Scholar 

  7. Jensen-Jarolim E, Singer J. Cancer vaccines inducing antibody production: more pros than cons. Expert Rev Vaccines. 2011;10(9):1281–9.

    Article  CAS  PubMed  Google Scholar 

  8. Jensen-Jarolim E, Singer J. Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology? Clin Exp Allergy. 2011;41(10):1337–40.

    Article  CAS  PubMed  Google Scholar 

  9. Weichselbaumer M, Willmann M, Reifinger M, Singer J, Bajna E, Sobanov Y, Mechteriakova D, Selzer E, Thalhammer JG, Kammerer R, Jensen-Jarolim E. Phylogenetic discordance of human and canine carcinoembryonic antigen (CEA, CEACAM) families, but striking identity of the CEA receptors will impact comparative oncology studies. PLoS Curr. 2011;3:RRN1223.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, Knittelfelder R, Daniels TR, Hobson PS, Beavil AJ, Spicer J, Nestle FO, Penichet ML, Gould HJ, Jensen-Jarolim E, Karagiannis SN. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-postive tumour cells. Cancer Immunol Immunother. 2009;58(6):915–30. Epub 2008 Oct 22.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Researcher of the month. Wien Klin Wochenschr 127, 81–82 (2015). https://doi.org/10.1007/s00508-015-0699-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-015-0699-5

Search

Navigation